[Beneficial effect of sulfasalazine in spondylarthropathy in 2 patients with HIV infection].
M Mijiyawa, Melguizo-Melguizo David
Abstract
M Mijiyawa, Melguizo-Melguizo David
Abstract
Two HIV-positive males aged 27 and 30 years, respectively, developed spondyloarthropathy with axial and appendicular joint involvement and recurrent diarrhea. Neither patient was able to discontinue nonsteroidal antiinflammatory drugs. Consequently, sulfasalazine was given in a daily dosage of 2 grams. Improvements in symptoms occurred in both patients within one month of initiation of sulfasalazine and persisted subsequently. No adverse effects were recorded. Although they require confirmation, these data suggest that sulfasalazine is of use for treating HIV-associated spondylarthropathies.
OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Two HIV-positive males aged 27 and 30 years, respectively, developed spondyloarthropathy with axial and appendicular joint involvement and recurrent diarrhea. Neither patient was able to discontinue nonsteroidal antiinflammatory drugs. Consequently, sulfasalazine was given in a daily dosage of 2 grams. Improvements in symptoms occurred in both patients within one month of initiation of sulfasalazine and persisted subsequently. No adverse effects were recorded. Although they require confirmation, these data suggest that sulfasalazine is of use for treating HIV-associated spondylarthropathies.
Key concepts: Sulfasalazine, Spondylarthropathies, Medicine, Spondyloarthropathy, Reactive arthritis, Diarrhea, Adverse effect, Internal medicine